These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 31740549)

  • 1. Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases.
    Tahvildari M; Dana R
    J Immunol; 2019 Dec; 203(11):2749-2755. PubMed ID: 31740549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-dose IL-2 therapy in autoimmune diseases: An update review.
    Zhang R; Zhao Y; Chen X; Zhuang Z; Li X; Shen E
    Int Rev Immunol; 2024 May; 43(3):113-137. PubMed ID: 37882232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of rapamycin and interleukin-2 on regulatory CD4+CD25+Foxp3+ T cells in mice after allogenic corneal transplantation.
    Wang X; Wang W; Xu J; Le Q
    Transplant Proc; 2013 Mar; 45(2):528-37. PubMed ID: 23267787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose interleukin-2 selectively expands circulating regulatory T cells but fails to promote liver allograft tolerance in humans.
    Lim TY; Perpiñán E; Londoño MC; Miquel R; Ruiz P; Kurt AS; Kodela E; Cross AR; Berlin C; Hester J; Issa F; Douiri A; Volmer FH; Taubert R; Williams E; Demetris AJ; Lesniak A; Bensimon G; Lozano JJ; Martinez-Llordella M; Tree T; Sánchez-Fueyo A
    J Hepatol; 2023 Jan; 78(1):153-164. PubMed ID: 36087863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How GRAIL controls Treg function to maintain self-tolerance.
    Fathman CG; Yip L; Gómez-Martín D; Yu M; Seroogy CM; Hurt CR; Lin JT; Jenks JA; Nadeau KC; Soares L
    Front Immunol; 2022; 13():1046631. PubMed ID: 36569931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.
    Bell CJ; Sun Y; Nowak UM; Clark J; Howlett S; Pekalski ML; Yang X; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Umana P; Klein C; Hosse RJ; Wicker LS; Peterson LB
    J Autoimmun; 2015 Jan; 56():66-80. PubMed ID: 25457307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease.
    Peterson LB; Bell CJM; Howlett SK; Pekalski ML; Brady K; Hinton H; Sauter D; Todd JA; Umana P; Ast O; Waldhauer I; Freimoser-Grundschober A; Moessner E; Klein C; Hosse RJ; Wicker LS
    J Autoimmun; 2018 Dec; 95():1-14. PubMed ID: 30446251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-34 deficiency impairs FOXP3
    Freuchet A; Salama A; Bézie S; Tesson L; Rémy S; Humeau R; Règue H; Sérazin C; Flippe L; Peterson P; Vimond N; Usal C; Ménoret S; Heslan JM; Duteille F; Blanchard F; Giral M; Colonna M; Anegon I; Guillonneau C
    Clin Transl Med; 2022 Aug; 12(8):e988. PubMed ID: 36030499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Restoring regulation - IL-2 therapy in systemic lupus erythematosus.
    Humrich JY; Riemekasten G
    Expert Rev Clin Immunol; 2016 Nov; 12(11):1153-1160. PubMed ID: 27283871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Next Frontier of Regulatory T Cells: Promising Immunotherapy for Autoimmune Diseases and Organ Transplantations.
    Terry LV; Oo YH
    Front Immunol; 2020; 11():565518. PubMed ID: 33072105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis.
    Buitrago-Molina LE; Pietrek J; Noyan F; Schlue J; Manns MP; Wedemeyer H; Hardtke-Wolenski M; Jaeckel E
    J Autoimmun; 2021 Feb; 117():102591. PubMed ID: 33387980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunity.
    Kosmaczewska A
    Int J Mol Sci; 2014 Oct; 15(10):18574-92. PubMed ID: 25322151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD4+ Foxp3+ regulatory T cells induced by TGF-β, IL-2 and all-trans retinoic acid attenuate obliterative bronchiolitis in rat trachea transplantation.
    Shi Q; Cao H; Liu J; Zhou X; Lan Q; Zheng S; Liu Z; Li Q; Fan H
    Int Immunopharmacol; 2011 Nov; 11(11):1887-94. PubMed ID: 21839859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study.
    Rosenzwajg M; Salet R; Lorenzon R; Tchitchek N; Roux A; Bernard C; Carel JC; Storey C; Polak M; Beltrand J; Amouyal C; Hartemann A; Corbeau P; Vicaut E; Bibal C; Bougnères P; Tran TA; Klatzmann D
    Diabetologia; 2020 Sep; 63(9):1808-1821. PubMed ID: 32607749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus.
    Mizui M; Tsokos GC
    Front Immunol; 2018; 9():786. PubMed ID: 29755456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy.
    Asano T; Meguri Y; Yoshioka T; Kishi Y; Iwamoto M; Nakamura M; Sando Y; Yagita H; Koreth J; Kim HT; Alyea EP; Armand P; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Maeda Y; Tanimoto M; Ritz J; Matsuoka KI
    Blood; 2017 Apr; 129(15):2186-2197. PubMed ID: 28151427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells.
    Kumar P; Saini S; Khan S; Surendra Lele S; Prabhakar BS
    Cell Immunol; 2019 May; 339():41-49. PubMed ID: 30482489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulating the regulators: Is introduction of an antigen-specific approach in regulatory T cells the next step to treat autoimmunity?
    Janssens I; Cools N
    Cell Immunol; 2020 Dec; 358():104236. PubMed ID: 33137651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic Immune Activation in Systemic Lupus Erythematosus and the Autoimmune PTPN22 Trp
    Ferreira RC; Castro Dopico X; Oliveira JJ; Rainbow DB; Yang JH; Trzupek D; Todd SA; McNeill M; Steri M; Orrù V; Fiorillo E; Crouch DJM; Pekalski ML; Cucca F; Tree TI; Vyse TJ; Wicker LS; Todd JA
    Front Immunol; 2019; 10():2606. PubMed ID: 31781109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vivo Expansion of Regulatory T Cells by Low-Dose Interleukin-2 Treatment Increases Allograft Survival in Corneal Transplantation.
    Tahvildari M; Omoto M; Chen Y; Emami-Naeini P; Inomata T; Dohlman TH; Kaye AE; Chauhan SK; Dana R
    Transplantation; 2016 Mar; 100(3):525-32. PubMed ID: 26881788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.